KYTX
NASDAQ
$7.24
Kyverna Therapeutics Inc (KYTX)
Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health challenges. Employing its proprietary genetically engineered T-cell technology, Kyverna aims to enhance the functionality of the immune system, offering specialized cellular therapies designed to improve patient outcomes substantially. With its commitment to developing cutting-edge therapeutic solutions and its strategic positioning within the growing biopharmaceutical sector, the company presents an appealing opportunity for institutional investors interested in the transformative potential of immunotherapy.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $30.40 (+319.89%)
Market Cap
$471M
Free Cash Flow Yield
-31.94%
Beta (5Y)
1.78
Price Chart
Valuation
Market Cap$471M
P/S3513.34
P/B2.46
Profitability
Gross Profit (TTM)-$126M
EBITDA-$162M
EPS-$3.10
Financial Health
Free Cash Flow Yield-31.94%
Growth & Risk
Beta (5Y)1.78
Sharpe Ratio1.04